vs

Side-by-side financial comparison of Chime Financial, Inc. (CHYM) and Healthpeak Properties (DOC). Click either name above to swap in a different company.

Healthpeak Properties is the larger business by last-quarter revenue ($719.4M vs $543.5M, roughly 1.3× Chime Financial, Inc.). Healthpeak Properties runs the higher net margin — 73.2% vs -10.1%, a 83.2% gap on every dollar of revenue. On growth, Chime Financial, Inc. posted the faster year-over-year revenue change (28.8% vs 3.1%). Healthpeak Properties produced more free cash flow last quarter ($357.0M vs $15.4M).

Chime Financial, Inc. is an American financial technology company based in San Francisco, California. It provides fee-free mobile banking services through two national banks, Stride Bank and The Bancorp Bank.

Healthpeak Properties, Inc. is an American real estate investment trust that invests in real estate related to the healthcare industry including senior housing, life science, and medical offices. It was organized in 2007 in Maryland and headquartered in Denver, Colorado with offices in Irvine, Nashville and San Francisco. As of December 31, 2019, the company owned interests in 617 properties.

CHYM vs DOC — Head-to-Head

Bigger by revenue
DOC
DOC
1.3× larger
DOC
$719.4M
$543.5M
CHYM
Growing faster (revenue YoY)
CHYM
CHYM
+25.8% gap
CHYM
28.8%
3.1%
DOC
Higher net margin
DOC
DOC
83.2% more per $
DOC
73.2%
-10.1%
CHYM
More free cash flow
DOC
DOC
$341.6M more FCF
DOC
$357.0M
$15.4M
CHYM

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CHYM
CHYM
DOC
DOC
Revenue
$543.5M
$719.4M
Net Profit
$-54.7M
$114.0M
Gross Margin
87.2%
Operating Margin
-11.9%
17.4%
Net Margin
-10.1%
73.2%
Revenue YoY
28.8%
3.1%
Net Profit YoY
-148.4%
2406.4%
EPS (diluted)
$-0.15
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHYM
CHYM
DOC
DOC
Q4 25
$719.4M
Q3 25
$543.5M
$705.9M
Q2 25
$528.1M
$694.3M
Q1 25
$702.9M
Q4 24
$698.0M
Q3 24
$421.9M
$700.4M
Q2 24
$384.2M
$695.5M
Q1 24
$606.6M
Net Profit
CHYM
CHYM
DOC
DOC
Q4 25
$114.0M
Q3 25
$-54.7M
$-117.1M
Q2 25
$-923.4M
$31.7M
Q1 25
$42.8M
Q4 24
$4.5M
Q3 24
$-22.0M
$85.9M
Q2 24
$385.0K
$146.0M
Q1 24
$6.7M
Gross Margin
CHYM
CHYM
DOC
DOC
Q4 25
Q3 25
87.2%
58.6%
Q2 25
87.3%
60.2%
Q1 25
61.1%
Q4 24
60.3%
Q3 24
87.3%
60.0%
Q2 24
86.9%
60.6%
Q1 24
59.8%
Operating Margin
CHYM
CHYM
DOC
DOC
Q4 25
17.4%
Q3 25
-11.9%
9.2%
Q2 25
-176.2%
5.7%
Q1 25
7.7%
Q4 24
-2.2%
Q3 24
-7.3%
14.1%
Q2 24
-2.5%
22.3%
Q1 24
3.7%
Net Margin
CHYM
CHYM
DOC
DOC
Q4 25
73.2%
Q3 25
-10.1%
-16.6%
Q2 25
-174.8%
4.6%
Q1 25
6.1%
Q4 24
0.7%
Q3 24
-5.2%
12.3%
Q2 24
0.1%
21.0%
Q1 24
1.1%
EPS (diluted)
CHYM
CHYM
DOC
DOC
Q4 25
$0.16
Q3 25
$-0.15
$-0.17
Q2 25
$-7.29
$0.05
Q1 25
$0.06
Q4 24
$0.02
Q3 24
$-0.34
$0.12
Q2 24
$0.00
$0.21
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHYM
CHYM
DOC
DOC
Cash + ST InvestmentsLiquidity on hand
$445.0M
$467.5M
Total DebtLower is stronger
$9.8B
Stockholders' EquityBook value
$1.4B
$7.5B
Total Assets
$2.0B
$20.3B
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHYM
CHYM
DOC
DOC
Q4 25
$467.5M
Q3 25
$445.0M
$91.0M
Q2 25
$868.3M
$89.4M
Q1 25
$70.6M
Q4 24
$119.8M
Q3 24
$270.8M
$180.4M
Q2 24
$295.4M
$106.9M
Q1 24
$101.8M
Total Debt
CHYM
CHYM
DOC
DOC
Q4 25
$9.8B
Q3 25
$9.1B
Q2 25
$9.0B
Q1 25
$8.9B
Q4 24
$8.7B
Q3 24
$8.6B
Q2 24
$8.6B
Q1 24
$8.8B
Stockholders' Equity
CHYM
CHYM
DOC
DOC
Q4 25
$7.5B
Q3 25
$1.4B
$7.6B
Q2 25
$1.4B
$7.9B
Q1 25
$8.2B
Q4 24
$8.4B
Q3 24
$-1.9B
$8.6B
Q2 24
$-1.9B
$8.8B
Q1 24
$8.9B
Total Assets
CHYM
CHYM
DOC
DOC
Q4 25
$20.3B
Q3 25
$2.0B
$19.6B
Q2 25
$1.9B
$19.8B
Q1 25
$19.8B
Q4 24
$19.9B
Q3 24
$20.0B
Q2 24
$20.2B
Q1 24
$20.5B
Debt / Equity
CHYM
CHYM
DOC
DOC
Q4 25
1.31×
Q3 25
1.20×
Q2 25
1.14×
Q1 25
1.08×
Q4 24
1.04×
Q3 24
1.00×
Q2 24
0.98×
Q1 24
0.99×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHYM
CHYM
DOC
DOC
Operating Cash FlowLast quarter
$17.5M
$1.3B
Free Cash FlowOCF − Capex
$15.4M
$357.0M
FCF MarginFCF / Revenue
2.8%
49.6%
Capex IntensityCapex / Revenue
0.4%
124.4%
Cash ConversionOCF / Net Profit
10.99×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHYM
CHYM
DOC
DOC
Q4 25
$1.3B
Q3 25
$17.5M
$315.0M
Q2 25
$2.7M
$363.5M
Q1 25
$279.4M
Q4 24
$1.1B
Q3 24
$318.2M
Q2 24
$316.2M
Q1 24
$152.6M
Free Cash Flow
CHYM
CHYM
DOC
DOC
Q4 25
$357.0M
Q3 25
$15.4M
Q2 25
$-888.0K
Q1 25
Q4 24
$333.7M
Q3 24
Q2 24
Q1 24
FCF Margin
CHYM
CHYM
DOC
DOC
Q4 25
49.6%
Q3 25
2.8%
Q2 25
-0.2%
Q1 25
Q4 24
47.8%
Q3 24
Q2 24
Q1 24
Capex Intensity
CHYM
CHYM
DOC
DOC
Q4 25
124.4%
Q3 25
0.4%
Q2 25
0.7%
Q1 25
Q4 24
105.6%
Q3 24
Q2 24
Q1 24
Cash Conversion
CHYM
CHYM
DOC
DOC
Q4 25
10.99×
Q3 25
Q2 25
11.48×
Q1 25
6.52×
Q4 24
235.43×
Q3 24
3.71×
Q2 24
2.17×
Q1 24
22.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHYM
CHYM

Payments Revenue$363.2M67%
Platform Related Revenue$180.4M33%

DOC
DOC

Segment breakdown not available.

Related Comparisons